Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Prostate Adenocarcinoma 1

Interventions

bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Radiosurgery 2Leuprolide 2Goserelin 2relugolix 1radium Ra 223 dichloride 1luprolide acetate gel depot 1histrelin 1flibanserin 1darolutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy 1Radiation 1Proton Therapy 1Magnetic Resonance Spectroscopy 1Flutamide 1Buserelin 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostate Adenocarcinoma × Salicylic Acid × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡